drugset / Trial / NCT02943668
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Phase 2
Terminated
2 enrolled
Fred Hutchinson Cancer Center
National Cancer Institute (NCI) · collabNovartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well deferasirox works in treating patients with very low, low, or intermediate-risk anemia or myelodysplastic syndrome that depends on red blood cell transfusions. Deferasirox may treat too much iron in the blood caused by blood transfusions.
Timeline
- Start
- 2017-03-02
- Primary completion
- 2018-12-17
- Completion
- 2018-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferasirox | Unknown | — | Oral |